SCHEMBL662972

SCHEMBL662972

C[CH]c1ccc(CC)cn1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
HRH3 Q9Y5N1 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
F2R P25116 1/20 0.34
RRM2 P31350 1/20 0.33
METAP2 P50579 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951852 0.85 KDM4E (0.59) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL12431662 0.85 KDM4E (0.59) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL31261054 0.85 KDM4E (0.59) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL951851 0.85 KDM4E (0.59) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL15007 0.83 KDM4E (0.61) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL934192 0.81 KDM4E (0.59) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL13621098 0.79 KDM4E (0.58) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL19735046 0.79 KDM4E (0.58) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL6181463 0.79 KDM4E (0.58) KDM4EL3MBTL1HRH3NPC1RAB9A
SCHEMBL9000467 0.78 KDM4E (0.56) KDM4EL3MBTL1HRH3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471782-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME Kowa Company, Ltd. (JP) 2012-07-04 EP disclosed
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME KOWA COMPANY, LTD. (JP) 2012-05-17 US disclosed
US-20120046308-A1 NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME KOWA COMPANY, LTD. (JP) 2012-02-23 US disclosed
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes ZHU JIE 2009-08-27 US disclosed
US-7541470-B2 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. (US) 2009-06-02 US disclosed
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. 2007-07-19 US disclosed
EP-1716144-A2 PROCESSES FOR MAKING PIOGLITAZONE AND COMPOUNDS OF THE PROCESSES Synthon B.V. (NL) 2006-11-02 EP disclosed
WO-2005080387-A2 PROCESSES FOR MAKING PIOGLITAZONE AND COMPOUNDS OF THE PROCESSES SYNTHON B.V. (NL) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 KDM4E 4654/4885L3MBTL1 4825/4885HRH3 4492/4885
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME AGTR2, AGTR1, PPARA KDM4E 4483/4885L3MBTL1 4709/4885HRH3 1472/4885
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 KDM4E 4654/4885L3MBTL1 4825/4885HRH3 4492/4885
US-20120046308-A1 NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME PPARA, PPARG, PPARD KDM4E 3100/4885L3MBTL1 3923/4885HRH3 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.